How Would You Value Company X? The Structured Approach

Introduction

"How would you value Company X?" is the most demanding technical question in investment banking interviews because it is open-ended. Unlike "walk me through a DCF" (which has a fixed structure) or "what multiple would you use for a bank?" (which has a specific answer), this question requires you to apply the entire valuation framework to a real company, demonstrating that you can think on your feet, select the right tools, and exercise judgment.

The company could be anything: Apple, a mid-cap healthcare services company, a pre-revenue biotech, a REIT, a bank, or a cyclical industrial. Your answer must adapt to the specific characteristics of the company, which is why this question reveals more about your understanding than any formula-based question can.

Step 1: Identify the Sector and Business Model

Before discussing any methodology, identify what kind of business the company is. This step determines everything else:

*"Company X is a [SaaS company / commercial bank / mining company / retail chain / etc.]. This determines the valuation approach because [explain why standard EV/EBITDA works or does not work for this type of business]."*

Refer to the sector selection framework to match the business type to the appropriate methodology.

Step 2: Select the Primary Methodology and Multiple

Based on the sector identification, choose the primary valuation metric:

Step 3: Describe the Triangulation

*"I would approach the valuation from multiple perspectives and triangulate. First, I would build trading comps using [X, Y, Z] as the closest public peers. Second, I would look at precedent transactions in the sector from the past 3-5 years. Third, I would build a DCF to estimate intrinsic value. [If relevant: And fourth, I would run an LBO analysis to determine the financial buyer floor.] I would synthesize the results on a football field chart."*

Step 4: Note Company-Specific Factors

This is where you demonstrate genuine engagement with the specific company, not just generic methodology:

*"For Company X specifically, I would pay particular attention to [a factor unique to this company]: for example, its patent cliff exposure, its customer concentration, its pending acquisition, its margin expansion trajectory, or its regulatory risk. This factor would influence where I expect the company to fall within the comps range."*

Step 5: Acknowledge What You Would Research

*"To refine the analysis, I would want to understand [management's guidance on growth, the competitive landscape, recent insider transactions, the debt maturity schedule, pending regulatory changes, etc.]. These factors would help me calibrate my assumptions."*

The power of the 5-step framework is that it adapts to any company. Here is how it changes for three very different sectors:

"How Would You Value JPMorgan?"

Step 1: *"JPMorgan is a diversified financial institution, specifically a large-cap commercial and investment bank. This immediately changes the valuation approach because debt is an operating asset for banks, not financing."*

Step 2: *"I would NOT use EV/EBITDA. The primary multiples are P/TBV (price-to-tangible book value) and P/E. The intrinsic model is a dividend discount model, discounting expected dividends at the cost of equity."*

Step 3: *"Comparable banks would include Bank of America, Wells Fargo, Citigroup, and Goldman Sachs. I would build a DDM using JPMorgan's projected earnings, payout ratio, and cost of equity."*

Step 4: *"JPMorgan-specific factors: its industry-leading ROTCE of approximately 20% (justifying a significant premium to peers), its diversified revenue base across consumer banking, commercial banking, and investment banking, and its strong position to benefit from higher interest rates through net interest income."*

This answer demonstrates the critical skill of knowing when the standard framework does NOT apply.

"How Would You Value a Clinical-Stage Biotech?"

Step 1: *"A pre-revenue clinical-stage biotech is valued entirely on its pipeline, not on current financials. EBITDA is negative and revenue is zero, so standard operating multiples are meaningless."*

Step 2: *"The primary methodology is risk-adjusted NPV (rNPV), which projects the commercial cash flows for each pipeline candidate assuming approval, then probability-weights them by the cumulative likelihood of clinical success. For relative valuation, I would use EV/Revenue or EV per pipeline asset against comparable pre-revenue biotech peers."*

Step 3: *"I would build rNPV models for each Phase II and Phase III asset, using clinical success probabilities from historical phase-gate data (approximately 30% for Phase II to approval, 60% for Phase III to approval). The discount rate in rNPV is moderate (8-12%) because the clinical risk is captured in the probability adjustments, not in the discount rate."*

This answer shows awareness of the sector-specific valuation approaches that distinguish strong candidates.

"How Would You Value a Gold Mining Company?"

Step 1: *"A gold mining company is valued on its reserves, not on its current earnings, because the reserves are a depleting asset and earnings swing with the gold price."*

Step 2: *"The primary methodology is reserve-based NAV: the sum of the NPV of each mine's cash flows over its life-of-mine plan. The relative metric is P/NAV. EV/EBITDA is supplementary but requires mid-cycle normalization because current EBITDA depends on the gold price."*

Step 3: *"I would use a 5% discount rate for gold (the convention for precious metals, lower than the 8-10% used for base metals) and the current forward curve or a consensus long-term gold price assumption."*

Sector-Appropriate Methodology Selection

The first and most critical judgment in any open-ended valuation question. The candidate must identify the sector and business model BEFORE discussing any methodology, because the sector determines which tools are appropriate. Using EV/EBITDA for a bank, a standard DCF for a pre-revenue biotech, or trailing multiples for a cyclical industrial at peak earnings are all fundamental errors that reveal the candidate does not understand when to apply which framework. The first 10 seconds of the answer (the sector identification) determine the interviewer's assessment.

Interviewers sometimes deliberately ask about a company in a sector the candidate is unlikely to have prepared. The goal is not to see if you know the specific sector's metrics but to test whether you can reason from first principles.

The framework still applies. Step 1 (identify the business model) is the key. Even if you have never studied utility valuation, you can reason: "This is a regulated utility. Its earnings are set by the regulator, so they are very predictable. That predictability makes a DDM or a DCF with high confidence in the projections appropriate. The standard multiple would be EV/EBITDA, and I would look at the regulated asset base as a key value driver."

The interviewer is not expecting you to know the specific P/FFO range for REITs or the convention for gold discount rates. They are testing whether you can identify the key characteristic of the business (regulated, pre-revenue, cyclical, asset-heavy) and select the appropriate framework.

The interviewer is not testing whether you know the "right" answer (there is no single right answer for any company). They are evaluating:

1. Can you identify the appropriate methodology? (Sector awareness) 2. Can you name specific comparable companies? (Market awareness) 3. Do you understand the triangulation framework? (Methodological completeness) 4. Can you identify company-specific value drivers? (Analytical depth) 5. Do you acknowledge uncertainty? (Intellectual honesty)

Triangulation (Verbal Answer Context)

When delivering the "how would you value Company X?" answer, triangulation means explicitly stating that you would approach the valuation from multiple perspectives (comps, precedent transactions, DCF, and potentially LBO or sector-specific methods) and synthesize the results on a football field chart. Mentioning triangulation signals that you understand valuation as a system of cross-checks, not as a single methodology applied in isolation. The strongest candidates go further by explaining how they would weight the methodologies: "For a sell-side M&A process with both strategic and financial buyers, I would weight precedent transactions and the LBO floor heavily because they directly reflect acquisition pricing."